PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Newest GO™ Peptides - Exendins - Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else
AnaSpec Introduces Newest GO™ Peptides - Exendins

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2009/02/27 - Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AnaSpec has added a wide selection of Exendin peptides to it’s GO™ Peptides line of on-demand peptides. Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else.

Fluorescein-Trp25-Exendin-4 (FLEX) is Exendin-4 with a fluorescein covalently attached to Trp at position 25. Useful for binding and characterization studies of the human GLP-1 receptor, FLEX is equipotent to GLP-1 (7-36)-amide and Exendin-4 as an inhibitor of [125I]-GLP-1 binding to the human GLP-1 receptor stably expressed in CHO cells.1 [Cys(HiLyte Fluor™ 647 C2 maleimide)]-Exendin -4 is Exendin-4 with an additional Cys added to the N-terminus. AnaSpec’s patented HiLyte Fluor 647 (Ex/Em=650 nm/675 nm) is attached to the Cys thiol moiety.

Exendin-3 and Exendin-4 are 39-amino acid peptides from exocrine glands that share about 50% sequence identity to Glucagon-Like-Peptide-1 (GLP-1) and are potent GLP-1R agonists. 2,3 Exendin-3 stimulates increases in cellular cAMP and amylase release from dispersed guinea pig pancreatic acini.4 Exendin-4 was originally isolated from the saliva of the lizard Heloderma suspectum. It is an insulinotropic agent which improves glucose tolerance in humans and animals with diabetes. It increases insulin sensitivity via a PI-3-kinase-dependent mechanism. In the human fetal pancreas, the proliferation and differentiation of endocrine precursor cells into insulin-producing ß-cells can be positively regulated by Exendin-4.5 Exendin-4 is an agonist and Exendin (9-39) is an antagonist of the action of GLP-I (7-36) amide on arterial blood pressure and heart rate.6

About AnaSpec

AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

References:
1. Chicchi GG. et al. Peptides 18, 319 (1997).
2. Goke, R. et al. J. Biol. Chem. 268, 19650 (1993).
3. Thorens, B. et al. Diabetes 42, 1678 (1993).
4. Eng, J. J. Biol. Chem. 265, 20259 (1990).
5. Movassat, J. et al. J. Clin. Endo. Metab. 87, 4775 (2002).
6. Barragan, JM. Regul. Peptides 67, 63 (1994).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Newest GO™ Peptides - Exendins

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)